BeiGene (NASDAQ:BGNE) is down 9% premarket on modest volume in reaction to results from a Phase 3 clinical trial, ASPEN, comparing BTK inhibitor Brukinsa (zanubrutinib) to AbbVie’s (NYSE:ABBV) Imbruvica (ibrutinib) in patients with a type of lymphoma called Waldenström’s macroglobulinemia (WM).
The study failed to achieve the primary endpoint of demonstrating zanubrutinib’s superiority to ibrutinib as measured by the proportion of patients experiencing either a complete response (CR) or very good partial response (VGPR) in up to three years.
In the overall patient population, the VGPR rate for zanubrutinib was 28.4% compared to 19.2% for ibrutinib.
In the relapsed/refractory population, the major response rate (partial response or better) was 78.3% for zanubrutinib and 80.2% for ibrutinib.
The safety profiles were generally similar.
Complete data will be submitted for presentation at a future medical conference.
ABBV is up a fraction premarket.
Related ticker: Johnson & Johnson (NYSE:JNJ)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.